AstraZeneca PLC is continuing to go big on antibody drug conjugates (ADCs), paying $1bn upfront for ex-Japan global development and commercialization rights to a second such asset from existing partner Daiichi Sankyo Co., Ltd., in a deal that could be worth up to $6bn in total to the Japanese pharma company including future regulatory and sales milestones.
The new agreement is for DS-1062, a TROP2 (trophoblast cell-surface antigen 2)-directed ADC again built using Daiichi’s proprietary DXd technology...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

